Garrett M. Winslow

Member vCard


  • Boston University (LLM, Taxation, 2005)
  • Suffolk University Law School (JD, 2004)
  • University of Washington (BA, 2001)

Bar Admissions

  • Massachusetts

Garrett’s practice focuses on corporate and securities law matters, with particular emphasis on biotechnology, pharmaceutical and life sciences companies.  

Issuers, investors and investment banks rely on Garrett's advice in structuring, preparing and completing IPOs, alternative public offerings, reverse merger transactions, public offerings, at-the-market offerings and registered direct offerings, as well as PIPEs and other private placements.  Garrett represents public companies in a variety of corporate governance and compliance areas, including SEC requirements, initial and continued exchange listing governance requirements, ISS requirements and FINRA requirements.

Garrett also advises investors and entrepreneurs of emerging private companies on corporate governance matters and capital raising efforts.  

Representative Transactions

  • Represented Synta Pharmaceuticals Corp. (NASDAQ: SNTA) in its anticipated reverse merger with Madrigal Pharmaceuticals, Inc.
  • Represented Morgan Stanley & Co. LLC, Leerink Partners LLC and UBS Securities LLC as lead underwriters in Acceleron Pharma Inc.’s (NASDAQ: XLRN) follow-on public offering
  • Represented a foreign private issuer in the biotech industry in its initial public offering until the company was acquired by a Fortune 500 pharmaceutical company
  • Represented OvaScience, Inc. (NASDAQ: OVAS) in multiple follow-on public offerings
  • Represented a private company in a cash tender offer to purchase $20 million of its shares of common stock
  • Represented Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Citigroup Global Markets Inc. as lead underwriters in Puma Biotechnology, Inc.’s (NASDAQ: PBYI) follow-on public offering
  • Represented Chyron Corporation (NASDAQ: CHYR) in its international business combination with Hego Aktiebolag
  • Represented NeuroMetrix, Inc. (NASDAQ: NURO) in multiple follow-on public offerings and multiple PIPE transactions
  • Represented EnerNOC, Inc. (NASDAQ: ENOC) in its initial public offering and multiple follow-on public offerings 
  • Represented Hampden Bancorp, Inc. in its mutual-to-stock conversion and initial public offering, and assisted with implementing a stock repurchase program and defending a proxy contest.
  • Represented Leerink Partners LLC as lead underwriter in a proposed initial public offering for a Canadian foreign private issuer in the biotech industry
  • Represented BG Medicine, Inc. in its initial public offering

Professional & Community Involvement

  • Greater Boston Chamber of Commerce: Boston Future Leaders (2013)
  • Member, Boston Bar Association